SAB Biotherapeutics Inc (NASDAQ:SABS) has a beta value of 0.49 and has seen 0.71 million shares traded in the recent trading session. The company, currently valued at $20.16M, closed the recent trade at $2.18 per share which meant it lost -$2.18 on the day or -49.90% during that session. The SABS stock price is -188.99% off its 52-week high price of $6.30 and 0.92% above the 52-week low of $2.16. If we look at the company’s 10-day average daily trading volume, we find that it stood at 59520.0 shares traded. The 3-month trading volume is 80.73K shares.
The consensus among analysts is that SAB Biotherapeutics Inc (SABS) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -1.21.
SAB Biotherapeutics Inc (NASDAQ:SABS) trade information
Sporting -49.90% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the SABS stock price touched $2.18 or saw a rise of 52.61%. Year-to-date, SAB Biotherapeutics Inc shares have moved -42.43%, while the 5-day performance has seen it change -40.49%. Over the past 30 days, the shares of SAB Biotherapeutics Inc (NASDAQ:SABS) have changed -46.73%. Short interest in the company has seen 36467.0 shares shorted with days to cover at 0.4.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 63.67% from the levels at last check today. The projected low price target is $3.0 while the price target rests at a high of $8.0. In that case, then, we find that the latest price level in today’s session is -266.97% off the targeted high while a plunge would see the stock gain -37.61% from the levels at last check today.
SAB Biotherapeutics Inc (SABS) estimates and forecasts
Figures show that SAB Biotherapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -21.99% over the past 6 months, with this year growth rate of 51.70%, compared to 16.40% for the industry. Revenue growth from the last financial year stood is estimated to be -39.94%.
5 analysts offering their estimates for the company have set an average revenue estimate of 120k for the current quarter. 3 have an estimated revenue figure of 333.33k for the next ending quarter. Year-ago sales stood 305.01k and 944.58k respectively for this quarter and the next, and analysts expect sales will shrink by -60.66% for the current quarter and -39.94% for the next.
SABS Dividends
SAB Biotherapeutics Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
SAB Biotherapeutics Inc (NASDAQ:SABS)’s Major holders
Insiders own 19.15% of the company shares, while shares held by institutions stand at 35.63% with a share float percentage of 44.08%. Investors are also buoyed by the number of investors in a company, with SAB Biotherapeutics Inc having a total of 28.0 institutions that hold shares in the company.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Sep 30, 2024, the former fund manager holds about 2.52% shares in the company for having 232.57 shares of worth $0.49 million while later fund manager owns 42.64 shares of worth $89961.0 as of Sep 30, 2024, which makes it owner of about 0.46% of company’s outstanding stock.
